Clinical, Genomic, and Pathology Real-World Data (RWD) Market Landscape Assessment

Secondary Research

• Compiled information on the offerings of the top 10 RWD players; gathered competitive landscape data regarding collaborations between biopharma and RWD providers; analyzed FDA guidelines regarding the use of RWD in regulatory submissions

Primary Research

• Conducted 20 in-depth interviews with senior-level stakeholders from small, medium, and large U.S. oncology-focused biopharma; capturing perspectives on RWD utility across the drug development pipeline (i.e., Discovery, Translational, Clinical Development, Med Affairs, RWE / HEOR).

Quantitative Analysis

• Projected competitor market share and overall RWD market penetration based on interviewee examples of RWD acquisitions; calculated the average per project/per license spend and annual RWD budgets by biopharma size, estimated growth trajectories of RWD split by cancer type and data acquisition/pricing model.

DeciBio

• established a “fact base” regarding the primary use cases, users, and unmet needs of clinical, genomic, and pathology RWD
• captured “voice-of-customer” feedback in an organic / blinded fashion to advice client on key offering additions and adjustments.
• semi-quantitatively assessed the RWD market size, penetration, and growth rate and provided splits based on data acquisition/pricing model.